De novo MET amplification in EGFR-mutant non-small cell lung cancer

被引：0
|
作者：
Lee, D. D. W. [1 ]
Wang, L. [2 ]
Lai, G. [2 ]
Lim, T. K. H. [2 ]
Tan, D. S. W. [2 ]
机构：
[1] Univ Malaya, Dept Clin Oncol, Fac Med, Kuala Lumpur, Malaysia
[2] Natl Canc Ctr Singapore, Dept Med Oncol, Singapore, Singapore
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
655P
引用
收藏
页码：S1649 / S1650
页数：3
相关论文
共 50 条
  • [21] ADAURA: The Splash of Osimertinib in Adjuvant EGFR-Mutant Non-small Cell Lung Cancer
    Ortega-Franco, Ana
    Rafee, Shereen
    ONCOLOGY AND THERAPY, 2022, 10 (01) : 13 - 22
  • [22] Neurological death in patients with EGFR-mutant non-small cell lung cancer.
    Ramotar, Matthew
    Barnes, Sierra
    Doherty, Mark
    Shultz, David Benjamin
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [23] EGFR-mutant non-small cell lung cancer in Aberdeen, Scotland - Treatment and outcomes
    El-Shakankery, K.
    Steven, E.
    Clark, C.
    Stilwell, C.
    Kerr, K.
    Nicolson, M.
    LUNG CANCER, 2017, 103 : S35 - S36
  • [24] CARDIOVASCULAR EVENTS IN PATIENTS WITH EGFR-MUTANT NON-SMALL CELL LUNG CANCER ON OSIMERTINIB
    Peleg, Ariel
    Ibtida, Ishmam
    Liu, Jennifer
    Steingart, Richard
    Yu, Anthony
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2021, 77 (18) : 3288 - 3288
  • [25] Optimization of Dosing for EGFR-Mutant Non-Small Cell Lung Cancer with Evolutionary Cancer Modeling
    Chmielecki, Juliann
    Foo, Jasmine
    Oxnard, Geoffrey R.
    Hutchinson, Katherine
    Ohashi, Kadoaki
    Somwar, Romel
    Wang, Lu
    Amato, Katherine R.
    Arcila, Maria
    Sos, Martin L.
    Socci, Nicholas D.
    Viale, Agnes
    de Stanchina, Elisa
    Ginsberg, Michelle S.
    Thomas, Roman K.
    Kris, Mark G.
    Inoue, Akira
    Ladanyi, Marc
    Miller, Vincent A.
    Michor, Franziska
    Pao, William
    SCIENCE TRANSLATIONAL MEDICINE, 2011, 3 (90)
  • [26] Differential response to a combination of full-dose osimertinib and crizotinib in a patient with EGFR-mutant non-small cell lung cancer and emergent MET amplification
    Zhu, Viola W.
    Schrock, Alexa B.
    Ali, Siraj M.
    Ou, Sai-Hong Ignatius
    LUNG CANCER-TARGETS AND THERAPY, 2019, 10 : 21 - 26
  • [27] Mutation tracking of a patient with EGFR-mutant lung cancer harboring de novo MET amplification: Successful treatment with gefitinib and crizotinib
    Zheng, Xuanxuan
    Zhang, Guowei
    Li, Peng
    Zhang, Mina
    Yan, Xiangtao
    Zhang, Xiaojuan
    Yang, Jinbo
    Li, Haixia
    Liu, Xiyang
    Ma, Zhiyong
    Wang, Huijuan
    LUNG CANCER, 2019, 129 : 72 - 74
  • [28] Transcriptomic Heterogeneity of EGFR-Mutant Non-Small Cell Lung Cancer Evolution Toward Small-Cell Lung Cancer
    Oh, Songji
    Koh, Jaemoon
    Kim, Tae Min
    Kim, Soyeon
    Youk, Jeonghwan
    Kim, Miso
    Keam, Bhumsuk
    Jeon, Yoon Kyung
    Ku, Ja-Lok
    Kim, Dong-Wan
    Chung, Doo Hyun
    Heo, Dae Seog
    CLINICAL CANCER RESEARCH, 2024, 30 (20) : 4729 - 4742
  • [29] Combined inhibition of MET and VEGF enhances therapeutic efficacy of EGFR TKIs in EGFR-mutant non-small cell lung cancer with concomitant aberrant MET activation
    Huang, Shanshan
    Long, Yaling
    Gao, Yuan
    Lin, Wanling
    Wang, Lei
    Jiang, Jizong
    Yuan, Xun
    Chen, Yuan
    Zhang, Peng
    Chu, Qian
    EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2024, 13 (01)
  • [30] Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis
    Gen, Soei
    Tanaka, Ichidai
    Morise, Masahiro
    Koyama, Junji
    Kodama, Yuta
    Matsui, Akira
    Miyazawa, Ayako
    Hase, Tetsunari
    Hibino, Yoshitaka
    Yokoyama, Toshihiko
    Kimura, Tomoki
    Yoshida, Norio
    Sato, Mitsuo
    Hashimoto, Naozumi
    BMC CANCER, 2022, 22 (01)
12345